Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 41 to 50 of 400 total matches.

Drugs for Hepatitis C Virus Infection

   
The Medical Letter on Drugs and Therapeutics • Oct 28, 2024  (Issue 1714)
-2769 The Medical Letter ® Vol. 66 (1714) October 28, 2024 170 GLECAPREVIR/PIBRENTASVIR — Mavyret ...
About 2.5 million persons in the US had hepatitis C between 2017 and 2020. Guidelines from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) on management of hepatitis C virus (HCV) infection were updated in 2023.
Med Lett Drugs Ther. 2024 Oct 28;66(1714):169-74   doi:10.58347/tml.2024.1714a |  Show IntroductionHide Introduction

In Brief: New Benzodiazepine Warnings

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2020  (Issue 1610)
. The Medical Letter ® Vol. 62 (1610) November 2, 2020 estazolam drug safety Doral diazepam Diastat clonazepam ...
The FDA now requires boxed warnings in the package inserts of benzodiazepines describing the potential for these drugs to be abused and misused and to cause addiction and physical dependence. Benzodiazepine labels have contained a boxed warning about a risk of serious drug interactions with opioids since 2016.
Med Lett Drugs Ther. 2020 Nov 2;62(1610):175 |  Show IntroductionHide Introduction

Minocycline Foam (Zilxi) for Rosacea

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
trials. 180 The Medical Letter ® Vol. 62 (1611) November 16, 2020 Table 2. Some Topical Drugs ...
The FDA has approved a 1.5% topical foam formulation of minocycline (Zilxi – Foamix) for treatment of inflammatory lesions of rosacea in adults. It is the only topical minocycline product approved for this indication. The same manufacturer markets minocycline foam 4% (Amzeeq) for treatment of acne in patients ≥9 years old.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):179-80 |  Show IntroductionHide Introduction

Metoclopramide Nasal Spray (Gimoti) for Diabetic Gastroparesis

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
The Medical Letter ® Vol. 63 (1615) January 11, 2021 gastroparesis total symptom scores significantly more ...
The FDA has approved Gimoti (Evoke), a nasal spray formulation of the dopamine-2 (D2) receptor antagonist metoclopramide, for relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Metoclopramide (Reglan, and generics) has been available for years in conventional and orally-disintegrating tablets and in an injectable formulation. It is the only drug that is FDA-approved for treatment of diabetic gastroparesis.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):5-7 |  Show IntroductionHide Introduction

Jatenzo - An Oral Testosterone for Hypogonadism

   
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021  (Issue 1627)
® Vol. 63 (1627) June 28, 2021 Increases in blood pressure can occur with Jatenzo; patients taking ...
An oral formulation of testosterone undecanoate (Jatenzo – Clarus) has been approved by the FDA for treatment of adult men with conditions associated with a deficiency of endogenous testosterone, such as Klinefelter syndrome, orchiectomy, toxic damage from chemotherapy or alcohol, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Jatenzo is not approved for treatment of low testosterone levels solely due to aging. It is the first oral testosterone formulation to be approved in the US.
Med Lett Drugs Ther. 2021 Jun 28;63(1627):103-4 |  Show IntroductionHide Introduction

Dasiglucagon (Zegalogue) for Severe Hypoglycemia

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
. Pediatr Diabetes 2021; 22:734. 133 The Medical Letter ® Vol. 63 (1631) August 23, 2021 treated ...
The FDA has approved dasiglucagon (Zegalogue – Zealand) for subcutaneous (SC) treatment of severe hypoglycemia in patients ≥6 years old with diabetes. Dasiglucagon is the third glucagon product to be marketed in the US that does not require reconstitution before administration; Gvoke, a SC formulation approved for use in patients ≥2 years old, and Baqsimi, an intranasal powder approved for use in patients ≥4 years old, have been available since 2019. Injectable glucagon emergency kits (GlucaGen HypoKit, and generics) have been available for years, but they require...
Med Lett Drugs Ther. 2021 Aug 23;63(1631):132-4 |  Show IntroductionHide Introduction

Remimazolam (Byfavo) for Short-Term Procedural Sedation

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2022  (Issue 1644)
. Remimazolam powder contains dextran 40; the drug is contraindicated for The Medical Letter ® Vol. 64 (1644 ...
The FDA has approved remimazolam (Byfavo – Acacia Pharma), an ultra-short-acting IV benzodiazepine, for induction and maintenance of sedation in adults undergoing procedures of up to 30 minutes' duration.
Med Lett Drugs Ther. 2022 Feb 21;64(1644):26-8 |  Show IntroductionHide Introduction

An EUA for Bebtelovimab for Treatment of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Mar 21, 2022  (Issue 1646)
. Accessed March 3, 2022. Pronunciation Key Bebtelovimab: beb” te low’ vi mab The Medical Letter ® Vol. 64 ...
The investigational monoclonal antibody bebtelovimab (LY-CoV1404 – Lilly) has been granted an FDA Emergency Use Authorization (EUA) for IV treatment of mild to moderate COVID-19 in patients ≥12 years old who weigh ≥40 kg and are at high risk of progressing to severe disease, including hospitalization and death, and for whom alternative treatment options are unavailable or inappropriate. Bebtelovimab is active against the Omicron variant of SARS-CoV-2; sotrovimab (VIR-7831) is the only other monoclonal antibody currently available for treatment of COVID-19 that is active...
Med Lett Drugs Ther. 2022 Mar 21;64(1646):41-2 |  Show IntroductionHide Introduction

A Ranibizumab Ocular Implant (Susvimo) for Age-Related Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • May 02, 2022  (Issue 1649)
of ranibizumab 0.5 mg every 4 weeks.5 The Medical Letter ® Vol. 64 (1649) May 2, 2022 72 The primary endpoint ...
The FDA has approved Susvimo (Genentech), a refillable permanent ocular implant containing the vascular endothelial growth factor (VEGF) inhibitor ranibizumab, for treatment of neovascular (wet) age-related macular degeneration (nAMD) in patients who have previously responded to at least two intravitreal injections of a VEGF inhibitor. Ranibizumab intravitreal injection (Lucentis) has been available since 2006 for monthly treatment of nAMD. The FDA has approved ranibizumab-nuna (Byooviz), a biosimilar of Lucentis and the first ophthalmologic biosimilar; it will be available in June...
Med Lett Drugs Ther. 2022 May 2;64(1649):71-2 |  Show IntroductionHide Introduction

Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo

   
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022  (Issue 1660)
® Vol. 64 (1660) October 3, 2022 159 1. Ruxolitinib (Opzelura) for atopic dermatitis. Med Lett Drugs ...
The 1.5% cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura – Incyte) has been approved by the FDA for topical treatment of nonsegmental vitiligo (NSV) in patients ≥12 years old. Opzelura is the first product to be approved by the FDA for this indication. It was previously approved for treatment of atopic dermatitis.
Med Lett Drugs Ther. 2022 Oct 3;64(1660):158-9 |  Show IntroductionHide Introduction